Welcome to our dedicated page for Pennant Group SEC filings (Ticker: PNTG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pennant Group, Inc. filings document the public reporting of a healthcare services holding company with operating subsidiaries in home health, hospice, home care and senior living. Recent Form 8-K reports furnish quarterly and annual results, Regulation FD investor materials, material agreements and amendments tied to acquisitions and financing arrangements.
Proxy filings cover governance, board matters, executive compensation and shareholder voting items. Other material-event amendments provide acquisition-related financial statements and pro forma information, while credit agreement disclosures describe term loans, leverage and coverage covenants, restrictions on indebtedness, liens, dispositions and restricted payments, and healthcare-law-related default provisions.
The Pennant Group, Inc. held its Annual Meeting of Stockholders on May 14, 2026, with 30,486,574 common shares present out of 34,953,297 shares entitled to vote as of March 17, 2026. Stockholders elected three Class I directors to serve until the 2029 Annual Meeting. They also ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026. In an advisory vote, stockholders approved the compensation of the company’s named executive officers as disclosed in the proxy materials.
The Pennant Group, Inc. reported solid growth for the quarter ended March 31, 2026. Revenue rose to $285.4 million from $209.8 million a year earlier, driven by expansion in home health, hospice and senior living services.
Income from operations increased to $17.3 million versus $12.7 million, while net income attributable to Pennant grew to $8.5 million, or $0.24 per diluted share, up from $7.8 million, or $0.22. Segment Adjusted EBITDAR from Operations rose to $53.1 million, reflecting stronger performance in both home health and hospice and senior living.
Operating cash flow improved compared with the prior year but remained a modest use of cash at $3.4 million. Pennant ended the quarter with $4.9 million in cash, total assets of $956.5 million, long-term debt of $164.7 million, and total equity of $389.4 million.
The Pennant Group, Inc. reported strong first quarter 2026 results, with revenue of $285.4 million, up 36.0% from the prior-year quarter. GAAP diluted earnings per share were $0.24, compared to $0.22 a year earlier, and adjusted diluted earnings per share were $0.32 versus $0.27.
Net income attributable to Pennant was $8.5 million, a 9.6% increase, while adjusted net income reached $11.5 million, up 19.8%. Consolidated Adjusted EBITDA rose to $21.7 million, a 32.6% increase. Home health and hospice revenue grew 43.3% to $229.1 million, and senior living revenue increased 12.6% to $56.3 million, supported by higher admissions, hospice census and steady senior living occupancy.
Pennant Group, Inc. director Christopher R. Christensen reported an acquisition of 1,900 shares of common stock as a share grant on April 15, 2026. The award was priced at $0.00 per share and increased his directly held position to 144,091 shares.
According to the disclosure, these 1,900 granted shares vest in three equal annual installments beginning April 15, 2027. The filing also notes additional indirect holdings totaling 623,347 shares through entities and family accounts referenced in the footnotes.
Nackel John G. reported acquisition or exercise transactions in this Form 4 filing.
Pennant Group director John G. Nackel received a grant of 1,900 shares of Common Stock as an equity award. The grant was recorded at a price of $0.0000 per share and is compensation-related rather than an open-market purchase.
These 1,900 shares vest in three annual installments beginning April 15, 2027, meaning the award will become fully owned over time if service conditions are met. Following this grant, Nackel holds 172,665 shares directly and 2,700 shares indirectly through the Nackel Family Trust dated June 30, 1997, where he and his spouse share voting and investment power.
Lamb Scott E reported acquisition or exercise transactions in this Form 4 filing.
Pennant Group, Inc. director Scott E. Lamb reported receiving a grant of 2,400 shares of Common Stock as a share award. The grant was at no cash cost per share. Following this award, his directly held position increased to 56,535 shares.
According to the accompanying note, the 2,400 granted shares will vest in three equal annual installments beginning April 15, 2027, meaning the award is subject to a multi-year service-based vesting schedule.
Pennant Group, Inc. Chief Operating Officer John J. Gochnour reported compensation-related equity grants and a correction to his reported holdings. On March 3, 2026, he was awarded 11,214 shares of Common Stock that vest immediately on that date, bringing his direct Common Stock holdings to 145,464 shares after the grant. On March 5, 2026, he received a stock option for 41,000 shares of Common Stock at an exercise price of $33.30 per share, vesting in five equal annual installments beginning March 5, 2027 and expiring March 5, 2036. The filing is amended to correct the amount of securities beneficially owned as of the reported transaction date.
Pennant Group, Inc. Chief Executive Officer Brent Guerisoli reported two compensation-related equity awards and an amendment correcting previously reported ownership. He received a grant of 45,000 stock options with an exercise price of $33.30 per share, exercisable into 45,000 shares of common stock and expiring on March 5, 2036. These options vest in five equal annual installments beginning March 5, 2027. He was also awarded 11,260 shares of common stock that vest immediately on March 3, 2026, bringing his directly held common shares to 93,238 after the grant.